Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter May 1, 2018

β-Trace protein in hemodialysis – comparison of different therapy modalities and high flux dialyzers

  • Sebastian Schwab EMAIL logo , Dominik Bös , Felix Hundt , Carola Ellen Kleine , Christian P. Strassburg and Rainer Peter Woitas

Corresponding author: Dr. med. Sebastian Schwab, Department of Internal Medicine I, Medical Clinic I – University of Bonn, Bonn, Germany, Phone: +49 228 287 11038, Fax: +49 228 287 11052 and Institute of Experimental Immunology, Rheinische-Friedrichs-Wilhelms University of Bonn, Bonn, Germany

  1. Author contributions: Dr. Sebastian Schwab: analysis and interpretation of data, drafting of the manuscript. Dr. Dominik Bös: acquisition, analysis and interpretation of data. Dr. Felix Hundt: acquisition, analysis and interpretation of data. Dr. Carola Ellen Kleine: acquisition, analysis and interpretation of data. Prof. Dr. Christian Strassburg: administrative support, reviewing the manuscript. Prof. Dr. Rainer Peter Woitas: study concept and design, acquisition, analysis and interpretation of data, drafting of the manuscript, obtaining funding, administrative support and study supervision. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: RPW received honoraria from Siemens, Marburg, Germany.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. White CA, Ghazan-Shahi S, Adams MA. β-Traceprotein: a marker of GFR and other biological pathways. Am J Kidney Dis 2015;65:131–46.10.1053/j.ajkd.2014.06.038Search in Google Scholar PubMed

2. Shafi T, Parekh RS, Jaar BG, Plantinga LC, Oberai PC, Eckfeldt JH, et al. Serum β-trace protein and risk of mortality in incident hemodialysis patients. Clin J Am Soc Nephrol 2012;7:1435–45.10.2215/CJN.02240312Search in Google Scholar PubMed PubMed Central

3. Bergstrom J, Wehle B. No change in corrected beta 2-microglobulin concentration after cuprophane haemodialysis. Lancet 1987;1:628–9.10.1016/S0140-6736(87)90266-2Search in Google Scholar

4. Donadio C, Tognotti D, Caponi L, Paolicchi A. β-Trace protein is highly removed during haemodialysis with high-flux and super high-flux membranes. BMC Nephrol 2017;18:68.10.1186/s12882-017-0489-6Search in Google Scholar PubMed PubMed Central

5. Hoffmann A, Nimtz M, Conradt HS. Molecular characterization of beta-trace protein in human serum and urine: a potential diagnostic marker for renal diseases. Glycobiology 1997;7: 499–506.10.1093/glycob/7.4.499Search in Google Scholar PubMed

6. Hirawa N, Uehara Y, Yamakado M, Toya Y, Gomi T, Ikeda T, et al. Lipocalin-type prostaglandin D synthase in essential hypertension. Hypertension 2002;39:449–54.10.1161/hy0202.102835Search in Google Scholar PubMed

Received: 2018-02-15
Accepted: 2018-03-28
Published Online: 2018-05-01
Published in Print: 2018-10-25

©2018 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 5.12.2023 from https://www.degruyter.com/document/doi/10.1515/cclm-2018-0178/html
Scroll to top button